Cara Therapeutics (NASDAQ: CARA) Shares Surge on Trial Results: U.S. Daily Market Movers

Published:

Small
cap stocks making big moves on Friday, June 20, 2014 (as of 4 pm EST)

Cara Therapeutics (NASDAQ: CARA)
shares jumped 20% to $17.51 on Friday after its development partner, Enteris
BioPharma, Inc., announced that Cara had dosed the first subjects in a further
Phase 1a/1b clinical trial of a tablet formulation of its peripherally-selective
kappa opioid agonist, CR845, for the treatment of acute and chronic pain. 

As well,
shares of Hercules Offshore, Inc. (NASDAQ: HERO)
slipped 12% to $4.36 on volume of more than 24.3 million shares as
the operator of a fleet of jackup rigs and liftboats provided a fleet
status report in which it said it would voluntarily forgo a three-year contract
previously received in Angola. 

Kite Pharma, Inc. (NASDAQ: KITE)
stock, meanwhile, popped 71% to $29 on its first day of trading Friday. The
clinical-stage biopharmaceutical company is focused on developing engineered
autologous T cell therapy products for the treatment of cancer.

Finally,
India Globalization Capital, Inc. (NYSE MKT:
IGC
) shares climbed 2% to $1.60 after the company launched an organic
produce platform that can be used to grow legal cannabis in the future. 

Related articles

Recent articles